Virginia

Virginia has rapidly ascended as a premier global hub for the life sciences, recently securing its position within the top three US Biopharma Clusters as part of the dynamic BioHealth Capital Region.

The Commonwealth is internationally recognized for its leadership in advanced pharmaceutical manufacturing, anchored by the Richmond-Petersburg "Medicines for All" corridor which focuses on end-to-end drug substance production and supply chain resilience.

High-value investments from industry giants like AstraZeneca, Eli Lilly and Merck underscore Virginia's reputation for "speed-to-market" capabilities and a world-class biotechnology workforce.

Beyond manufacturing, the state excels in healthcare innovation, particularly through pioneering work in focused ultrasound, neurosciences and cancer immunotherapy at the University of Virginia (UVA) Health.

Academic research is further bolstered by Virginia Commonwealth University (VCU), which hosts the nation's first PhD program in pharmaceutical engineering, bridging the gap between laboratory discovery and commercial scale.

The newly established Paul and Diane Manning Institute of Biotechnology is set to accelerate this translational research, focusing on next-generation cellular therapies and personalized medicine.

Regional innovation districts in Northern Virginia and the VA Bio+Tech Park provide critical wet lab infrastructure and incubator support for emerging medical device and healthtech startups.

With a strategic focus on continuous manufacturing and AI-driven R&D, Virginia offers a robust, low-risk environment for global life sciences firms seeking a rapidly deployable platform.

This collaborative ecosystem, supported by aggressive state-led talent accelerators, ensures Virginia remains at the forefront of global health security and medical breakthroughs.